GlassScriptPhysician profile
Rose R Mueller
NPI 1336697408
$1,092.99
in general payments reported to CMS, 2019-2025
20 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.30 · 2022: $346 · 2023: $225 · 2024: $252 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $216.55 | 2021-2024 | |
| Novo Nordisk INC | $153.30 | 2021-2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $135.04 | 2022-2024 | Austedo Xr, Austedo |
| Lilly USA, LLC | $115.21 | 2022-2025 | Mounjaro, Zepbound |
| Gilead Sciences, INC. | $90.24 | 2021-2025 | Descovy |
| Otsuka America Pharmaceutical, INC. | $76.43 | 2021-2025 | Rexulti |
| Alkermes, INC. | $48.53 | 2022-2023 | Vivitrol |
| Viiv Healthcare Company | $36.71 | 2023-2025 | Cabenuva, Apretude |
| Braeburn INC. | $29.59 | 2024 | Brixadi |
| Merck Sharp & Dohme LLC | $23.87 | 2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Sanofi Pasteur INC. | $23.15 | 2022 | |
| Organon LLC | $22.27 | 2023 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.76 | 2021 | |
| Hologic Sales and Service, LLC | $17.29 | 2024 | Thinprep 2000 Processor, Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.15 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $17.07 | 2025 | Gvoke Hypopen |
| Ardelyx, INC. | $14.46 | 2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $13.34 | 2022 | |
| Noven Therapeutics, LLC | $13.16 | 2024 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.